VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board
09 Julio 2024 - 6:00AM
Business Wire
Significant leadership and expertise in
central nervous system diseases
VectorY Therapeutics, a biotech company developing innovative
vectorized antibody therapies for the treatment of
neurodegenerative diseases, announces the appointment of Adam
Rosenberg as the new Chair of the Board.
Boston-based Mr Rosenberg brings over 20 years of experience in
building and leading life sciences companies, primarily in the
neuroscience space. He replaces Dr Carlo Incerti who is stepping
down from the company’s board.
The appointment comes at a pivotal time for VectorY as the
company advances towards clinical development with a pipeline of
strongly differentiated vectorized antibody treatments for
neurodegenerative disorders.
“As we welcome Adam to VectorY as Chair of the Board, I would
also like to thank Carlo for his leadership, guidance and
dedication to VectorY since our founding,” commented Sander van
Deventer, Founder and CEO of VectorY. “Adam is a seasoned
biotech and independent executive with a proven track record in
building successful businesses and teams. I am excited to be
working with Adam and our board as VectorY advances to its next
phase of growth, from a preclinical to clinical stage company, and
as we expand our footprint in the US.”
“I am delighted to join VectorY at such a pivotal moment in the
company’s development. The team has already made significant
strides in researching and developing novel treatments with
disease-modifying potential for ALS and other neurodegenerative
diseases. I look forward to leveraging my experience and expertise
to help drive VectorY's pioneering efforts in this field and be a
part of the company’s future growth,” added Adam Rosenberg,
Chair of the Board at VectorY.
Adam is Chair of the Board of Directors at Seamless Therapeutics
and Ambagon Therapeutics, and also serves as a Director on the
boards of other venture-backed and public biotechnology companies.
He was the founding CEO of Aliada Therapeutics, Athenen
Therapeutics (merged with Eliem Therapeutics: ELYM) and Sionna
Therapeutics. Prior to that, he was President, CEO and member of
the Board of Directors of Rodin Therapeutics until its 2019
acquisition. Adam also served as CEO and Co-Founder of Link
Medicine, a company focused on developing disease-modifying
neurodegenerative therapies and as CEO and Co-Founder of Teleos
Therapeutics, a neuroscience drug discovery platform company.
A high resolution picture of Adam Rosenberg is available on
request.
Notes to Editors
About VectorY
VectorY is on a mission to provide patients with
neurodegenerative diseases a longer, better life by creating
transformative vectorized antibody treatments. Our platform
combines the promise of precise therapeutic antibodies with
one-time AAV-based delivery to the CNS. Unique in-house expertise
in antibodies, AAV vectors, protein degradation, manufacturing and
neuroscience drives the rapid development of much needed
disease-modifying therapies for neurodegenerative diseases such as
ALS. For more information, see www.Vectorytx.com.
About VTx-002
VTx-002 is being developed to delay disease progression and
preserve the quality of life of ALS patients. VTx-002, currently in
preclinical development, is a vectorized antibody that selectively
clears misfolded and aggregated TDP-43 from the cytoplasm of
neuronal cells. Thereby, it restores the essential function of
TDP-43 in the nucleus leading to preservation of neuronal cell
function and health.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240709920280/en/
VectorY Therapeutics B.V. Sander van Deventer, CEO E-mail:
info@vectorytx.com Elena Ritsou, CCO Email:
elena.ritsou@vectorytx.com Tel: +31 681 174 072 Instinctif Partners
(media enquiries) Melanie Toyne-Sewell / Katie Duffell E-mail:
VectorY@instinctif.com Tel: +44 20 7457 2020